• Publications
  • Influence
Lurasidone : in the treatment of schizophrenia.
TLDR
Lurasidone was generally well tolerated over the short and longer term, and was associated with a low risk of QT interval prolongation, weight gain, metabolic disturbances and hyperprolactinaemia. Expand
Zoster Vaccine (Zostavax®)
TLDR
Zoster vaccine had continuing efficacy in a Shingles Prevention Study sub-population followed for 7 years post-vaccination and was generally well tolerated in older adults. Expand
Mirabegron: A Review of Its Use in Patients with Overactive Bladder Syndrome
TLDR
Oral mirabegron 25 or 50 mg once daily is an efficacious new treatment for overactive bladder syndrome with a favourable tolerability profile and carries a low risk of QT interval prolongation. Expand
S-1 (Teysuno®): A Review of Its Use in Advanced Gastric Cancer in Non-Asian Populations
TLDR
Overall, S-1 plus cis platin was better tolerated than 5-FU plus cisplatin, with significantly lower rates of haematological, some gastrointestinal tract and other adverse events, serious adverse events and deaths resulting from toxicity, along with significantly fewer haem atological and renal function abnormalities. Expand
Ibrutinib: First Global Approval
TLDR
Ibrutinib has been approved in the USA for the treatment of MCL in previously treated patients and is one of the first approvals through the US FDA's Breakthrough Therapy Designation Pathway and an application has been filed in the EU seeking regulatory approval in this indication. Expand
Secukinumab: First Global Approval
TLDR
The milestones in the development of secukinumab leading to its first approval for the treatment of adult patients with psoriasis and psoriatic arthritis are summarized. Expand
Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis
TLDR
Fingolimod is an efficacious therapy for RRMS that reduces relapses, disability progression, new brain lesions and loss of brain volume and provides a useful alternative treatment in patients with RRMS who have responded poorly to other DMAs. Expand
Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.
TLDR
Pre-planned subgroup analyses in Asian patients and non-smokers showed that in these subgroups gefitinib prolonged OS, and that EGFR biomarkers predicted a positive response to gef itinib, which was associated with significantly fewer haematological and neurological adverse effects than comparator chemotherapy regimens. Expand
Rotigotine Transdermal Patch
TLDR
Rotigotine offers a novel approach to the treatment of Parkinson’s disease and, given its ease of administration, efficacy in reducing disabling motor and non-motor symptoms, and acceptable tolerability profile, it has the potential to be an attractive treatment option for this highly debilitating disease. Expand
Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.
TLDR
The evidence to date establishes anastrozole as a valuable adjuvant and extended adjUvant treatment for postmenopausal women with hormone receptor-positive, early-stage breast cancer. Expand
...
1
2
3
4
5
...